FDA proposed to exclude compounded GLP-1s from the 503B bulks list (April 30, 2026) On April 30, 2026 , the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list the list that lets large outsourcing pharmacies legally compound those drugs from raw materials (source: fda.gov press announcement, April 30, 2026
For years, many of our members struggled with traditional diet and exercise advice that failed to account for hormonal imbalances and metabolic set points
Coombes, J
"Effect of GLP-1 receptor agonist on brain glucose metabolism in Alzheimers." Diabetes, 2016
Houten, S
Cavaliers at Thunder (1 ET, ABC): Winners of seven straight and 5-0 since pairing James Harden with Donovan Mitchell, Cleveland is pressuring the Knicks for 3rd place in the East, while a short-handed OKC team has won three of its last four